What Is Pantethine (Vitamin B5 Derivative) and Does It Actually Help With Psoriasis?

Pantethine is a dimeric, biologically active form of pantothenic acid (vitamin B5) that the body uses as a precursor to coenzyme A, a molecule central to energy metabolism and fatty acid synthesis. Unlike plain pantothenic acid, pantethine has long been studied for its ability to lower blood cholesterol and triglycerides — and research published in the Journal of Experimental Medicine on October 27, 2026 now suggests it may also calm the immune dysfunction driving psoriasis.

The finding emerged from a multi-stage investigation by scientists at the State Key Laboratory of Biomedical Analysis in Beijing, who traced psoriasis inflammation to a previously underappreciated metabolic pathway involving enzymes called Vanins. When Vanin activity is abnormally high — as it is in dendritic cells from psoriasis patients — pantethine gets broken down too rapidly, cholesterol accumulates inside immune cells, and a chronic inflammatory loop begins. Restoring pantethine levels interrupted that loop in laboratory experiments, in mouse models, and in a preliminary human trial.

Below is a side-by-side overview of the key evidence tiers from the 2026 research, alongside what is already established about pantethine's safety and cholesterol effects:

Evidence Tier	What Was Tested	Key Finding	Confidence Level
Laboratory (cell studies)	Vanin enzyme activity in dendritic cells from psoriasis & lupus patients	High Vanin activity depleted pantethine, raised intracellular cholesterol, hyperactivated immune cells	Mechanistic; high internal validity
Animal model (mice)	Pantethine supplementation and Vnn3 gene knockout in psoriasis-like inflammation	Mice given pantethine developed milder skin symptoms, less thickening, fewer inflammatory immune cells	Promising; species-translation uncertainty
Human trial (n = 24, 12 weeks)	Oral pantethine 300 mg twice daily added to calcipotriene/betamethasone ointment vs. ointment alone	Greater psoriasis severity score improvement in pantethine group; effect strongest in high-cholesterol patients; no adverse effects reported	Proof-of-concept only; small, single-center
Cholesterol lowering (prior literature)	Pantethine supplements in hyperlipidemia studies	Reduces total cholesterol, LDL, and triglycerides; raises HDL	Established but requires more large-scale trials per NIH ODS
Safety profile	Pantothenic acid / pantethine at various doses	Safe even at high doses; very high intake (e.g., 10,000 mg/day pantothenic acid) may cause GI upset	Well-established; no known drug interactions

What exactly is pantethine, and how is it different from vitamin B5?

Pantothenic acid — commonly called vitamin B5 — is an essential water-soluble vitamin found in nearly every food, from shiitake mushrooms and avocados to beef, eggs, and whole grains. Adults need about 5 mg per day, a threshold most people in the United States meet through diet alone.

Pantethine is the stable, oxidized dimer of pantetheine, which is itself the direct precursor to coenzyme A. In practical terms, pantethine sits one biochemical step closer to coenzyme A than plain vitamin B5 does — which is why it produces different physiological effects at supplemental doses. When you take pantethine as a supplement, Vanin enzymes in your cells cleave it into pantothenic acid, which cells then convert to coenzyme A for energy metabolism.

This conversion step is exactly where the psoriasis story gets interesting. The 2026 JEM study found that when Vanin enzymes are overactive — as they are in inflamed dendritic cells — pantethine is consumed too quickly, leaving cells depleted. That depletion is not metabolically neutral: it triggers a compensatory surge in cholesterol synthesis inside the immune cell itself.

Pantethine is available in dietary supplements either on its own or as part of B-complex formulations. The NIH Office of Dietary Supplements notes that pantethine is one of the common supplement forms of pantothenic acid, alongside calcium pantothenate, and that research has not established any one form as definitively superior for general nutritional purposes.

How does psoriasis actually develop, and where do dendritic cells fit in?

Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by rapid keratinocyte (skin cell) proliferation that produces the thick, scaly plaques most people associate with the condition. It affects roughly 2–3% of the global population and frequently co-occurs with cardiometabolic conditions including dyslipidemia, hypertension, obesity, and type 2 diabetes — a pattern that has long hinted at a systemic metabolic component to the disease.

At the cellular level, psoriasis is driven by a feedback loop between the innate and adaptive immune systems. Dendritic cells are specialized antigen-presenting immune cells that act as coordinators of the body's defenses: they capture foreign or abnormal molecules, process them, and present fragments to T cells, which then mount a targeted immune response. Dendritic cells also release cytokines — chemical signaling proteins — that recruit additional immune cells and amplify inflammation.

In healthy skin, this process is tightly regulated. In psoriasis, dendritic cells become chronically hyperactivated, releasing excessive cytokines and continuously stimulating T cells even in the absence of a genuine threat. The result is a self-sustaining inflammatory loop that drives the rapid skin cell turnover and plaque formation that define the disease.

The 2026 research team identified unusually high levels of Vanin enzymes specifically in dendritic cells from psoriasis patients — and from patients with several other autoimmune diseases, suggesting the pathway may not be unique to psoriasis. When the scientists reduced Vanin levels experimentally, dendritic cells became less active and less capable of stimulating T cells, pointing directly at Vanin activity as a driver of immune hyperactivation.

What is the Vanin-pantethine-cholesterol axis, and why does it matter?

The Vanin-pantethine-cholesterol axis is the metabolic pathway that the 2026 JEM study identified as a key regulator of dendritic cell activation. Understanding it requires following three linked steps.

First, Vanin enzymes (particularly Vnn1 and Vnn3) are upregulated in the dendritic cells of people with psoriasis and other autoimmune conditions. These enzymes break pantethine down into pantothenic acid at an accelerated rate, depleting the intracellular supply of pantethine.

Second, pantethine depletion removes a brake on cholesterol synthesis. Pantethine normally inhibits the enzyme HMG-CoA reductase — the same enzyme targeted by statin drugs — so when pantethine levels fall, cholesterol production inside the dendritic cell rises. As the HealthandFamily.in analysis explains, this surplus cholesterol forms rigid membrane microdomains called "lipid rafts" that function as amplification hubs for inflammatory signaling.

Third, cholesterol-enriched lipid rafts make dendritic cells hypersensitive to activation signals, causing them to release more cytokines and more aggressively stimulate T cells — perpetuating the psoriatic inflammatory loop.

The researchers confirmed this chain of events by showing that adding pantethine back to depleted dendritic cells reduced cholesterol accumulation and suppressed immune activation. Mice lacking the Vnn3 gene in their dendritic cells developed less severe psoriasis-like inflammation, and mice given pantethine supplements developed milder skin symptoms with less skin thickening and fewer inflammatory immune cells in affected tissue.

"Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression," said lead researcher Wei-Na Zhang. "But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored."

The connection between cholesterol and immune activation is not entirely new — elevated blood cholesterol has previously been identified as a risk factor for psoriasis — but the 2026 study is the first to map the specific intracellular mechanism linking Vanin activity, pantethine depletion, and dendritic cell hyperactivation.

What did the human clinical trial actually show?

The human portion of the study was a randomized, single-center, investigator-initiated clinical trial. Published data show that 24 patients with plaque psoriasis were enrolled. All participants received standard topical treatment — a calcipotriene/betamethasone ointment, combining a vitamin D derivative that regulates skin cell growth with a corticosteroid that reduces inflammation. Half also took oral pantethine at 300 mg twice daily (600 mg total per day) for 12 weeks.

After 12 weeks, the pantethine group showed greater improvement in psoriasis severity scores than the group receiving topical treatment alone. The benefit was particularly pronounced among participants who had elevated blood cholesterol levels at the start of the trial — a finding consistent with the proposed mechanism, since those patients would theoretically have the most to gain from pantethine's cholesterol-modulating effects.

No treatment-related adverse effects were reported in the pantethine group, which aligns with the established safety profile of pantethine supplements more broadly.

The limitations are substantial, and the researchers themselves are explicit about them. Twenty-four patients at a single center over 12 weeks cannot establish efficacy. The trial was not blinded in a way that rules out placebo effects. Wei-Na Zhang stated directly: "Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation."

The human trial shows the idea is worth pursuing — not that pantethine is a proven psoriasis treatment.

How does the 2026 JEM study connect to other pantethine skin research?

The JEM study is not the only 2026 research to examine pantethine in psoriasis. A separate paper published in Experimental Dermatology (November 2026) by researchers at Mahidol University in Bangkok took a different but complementary approach. That study used a full-thickness 3D human psoriatic skin model — a laboratory construct that mimics the architecture of real skin — to investigate pantethine's effects at the epidermal level.

Using histopathological analysis, immunohistochemistry, quantitative RT-PCR, and proteomic profiling, the Mahidol team found that pantethine significantly reduced epidermal thickening and normalized multiple psoriasis-associated molecular signatures. Proteomic analysis revealed coordinated changes in vesicle-associated proteins, cytoskeletal proteins, and extracellular matrix components — suggesting pantethine influences not just immune cell behavior but also the structural biology of the skin itself.

The PubMed abstract describes pantethine as "a stable vitamin B5 derivative with lipid-modulatory and anti-inflammatory properties" that has been "implicated in regulation of cellular stress responses and membrane-associated signalling pathways." Two independent research groups — one focused on immune cell metabolism, one on epidermal biology — arriving at pantethine through different experimental routes strengthens the biological plausibility of the compound's relevance to psoriasis, even if neither study alone is definitive.

Is pantethine safe to take, and are there any drug interactions?

Pantethine has a well-established safety profile. The NIH Office of Dietary Supplements confirms that pantothenic acid is safe even at high doses, with the only documented adverse effect being gastrointestinal upset (stomach pain and diarrhea) at very high intakes such as 10,000 mg per day — far above any dose used in psoriasis research. Pantothenic acid is not known to interact with any medications.

The 300 mg twice-daily dose used in the 2026 JEM trial produced no reported adverse effects in any of the 24 participants. This is consistent with pantethine's long history of use as a cholesterol-lowering supplement, where doses in the range of 600–1,200 mg per day have been studied without significant safety signals.

A few practical caveats apply. The 12-week trial duration does not address long-term safety. Patients with psoriasis frequently take multiple medications — including immunosuppressants, biologics, and topical corticosteroids — and while no interactions with pantethine are currently documented, anyone managing psoriasis with prescription therapies should discuss any supplement additions with their dermatologist or prescribing physician. The NIH also notes that people with a rare inherited disorder called pantothenate kinase-associated neurodegeneration cannot process pantothenic acid normally and should seek specific medical guidance.

Who might benefit most from pantethine, based on current evidence?

The 2026 JEM trial data suggest that psoriasis patients with elevated blood cholesterol levels showed the greatest improvement when pantethine was added to standard topical treatment. This makes biological sense within the proposed mechanism: if the Vanin-pantethine-cholesterol axis is the relevant pathway, patients whose cholesterol metabolism is already dysregulated would have more room for pantethine to make a difference.

Psoriasis and dyslipidemia frequently co-occur. As the HealthandFamily.in analysis notes, psoriasis is a systemic inflammatory condition that commonly presents alongside cardiometabolic comorbidities including obesity, hypertension, diabetes, and dyslipidemia. Patients in this overlapping group — psoriasis plus elevated cholesterol — represent a subpopulation for whom pantethine's dual action (cholesterol modulation plus immune calming) could theoretically be most relevant.

It would be premature, though, to recommend pantethine specifically for this group based on a 12-patient subgroup within a 24-patient trial. The subgroup finding is hypothesis-generating, not confirmatory.

The broader implication of the research — that the Vanin-pantethine pathway may be relevant across multiple dendritic cell-mediated autoimmune diseases, not just psoriasis — is also worth noting. The researchers observed elevated Vanin levels in dendritic cells from patients with lupus as well, and pantethine suppressed immune activation in those cells too. Whether this translates to clinical benefit in lupus or other autoimmune conditions is entirely unknown at this stage.

What does this mean for standard psoriasis treatment, and what comes next?

Standard psoriasis treatment is not going anywhere. Topical corticosteroids, vitamin D analogues (like calcipotriene), retinoids, phototherapy, and — for moderate-to-severe disease — systemic therapies including biologics targeting TNF-alpha, IL-17, and IL-23 pathways remain the evidence-based backbone of psoriasis management. The 2026 pantethine research does not challenge any of these approaches; it investigates pantethine specifically as an adjunct, added on top of standard care.

As ScieNow summarizes, the small human trial "cannot establish whether the improvements resulted from the same cellular mechanism demonstrated in the lab" — a reminder that biological plausibility and clinical efficacy are not the same thing. Many compounds that work elegantly in cell studies and mouse models fail to produce meaningful benefits in larger human populations.

What the research does establish is a credible, mechanistically coherent hypothesis: that the Vanin-pantethine-cholesterol axis regulates dendritic cell activation, that this axis is dysregulated in psoriasis, and that restoring pantethine levels may help correct that dysregulation. That hypothesis now needs testing in adequately powered, multicenter, randomized controlled trials with longer follow-up periods, standardized outcome measures, and ideally biomarker endpoints — such as intracellular cholesterol levels and Vanin activity — that can confirm whether the proposed mechanism is actually operating in human patients.

The research team frames the findings precisely this way. "Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell-mediated autoimmune diseases," Zhang said — language that positions the work as a foundation, not a conclusion.

Should you start taking pantethine for psoriasis right now?

Not without talking to your dermatologist first, and not with the expectation that it will replace your current treatment.

Pantethine is widely available, inexpensive, and has a strong safety record at the doses studied. Those facts make it tempting to self-supplement, especially for patients frustrated by the limitations or side effects of existing therapies. But the evidence base for psoriasis specifically consists of one small human trial and supporting laboratory and animal data — a starting point for research, not a clinical recommendation.

There are also practical considerations. Psoriasis management is highly individualized. Patients on immunosuppressive biologics, methotrexate, or cyclosporine are managing complex immune modulation, and adding any supplement — even a generally safe one — warrants a conversation with the prescribing physician. Patients whose psoriasis is well-controlled on current therapy have less to gain from adding an unproven adjunct than those whose disease is inadequately managed.

If you have psoriasis and elevated cholesterol, the case for discussing pantethine with your doctor is somewhat stronger, given that the trial's most notable improvements appeared in that subgroup. But "discuss with your doctor" is genuinely the right advice here, not a reflexive hedge — the data are too preliminary to support a blanket recommendation.

What the 2026 research does offer is a genuinely novel mechanistic insight into how metabolism and immunity intersect in psoriasis, and a plausible new target for future drug development. Whether that target ultimately yields a meaningful therapy — as a supplement, a Vanin inhibitor drug, or something else — will depend on the larger trials that the researchers are now calling for.

For anyone managing psoriasis and curious about the role nutrition and metabolic health play in skin inflammation, this research is a compelling reminder that the skin does not exist in isolation from the rest of the body's biochemistry. The connection between cholesterol metabolism and immune hyperactivation in psoriasis is not just a curiosity — it may eventually point toward genuinely new ways to manage a condition that affects tens of millions of people worldwide.